跳至主要内容

The prokaryotic expression system (E. coli expression system)

 The prokaryotic expression system (E. coli expression system) is the earliest developed and most widely used classic expression system in gene expression technology. In recent decades, the E. coli expression system has also been continuously developed and improved, and has been widely used by scientific research and industrial users for various Recombinant protein expression. Compared with other expression systems, it has the characteristics of high expression level of target gene, short culture period, strong anti-pollution ability and relatively low cost.

Medicilon researchers have established a mature E. coli expression and purification service platform to provide expression and purification services including various recombinant proteins and their complexes in E. coli.

Prokaryotic expression system (E. coli expression system) service items:

   ❖Recombinant plasmid construction;

   ❖Recombinant expression test;

   ❖Soluble expression condition test;

   ❖Small-scale protein expression and purification (2L medium culture product);

   ❖Large-scale protein expression and purification (above 10L).

StepExperiment contentExperiment timeRemarks
1Recombinant plasmid constructionfor 2 weeksYou can choose different vectors, different tags His, Trx, GST, SUMO…
2Recombinant expression test1 weekDifferent expression strains are optional
3Soluble expression test1-2 weeksDifferent inducers, induction temperature, can also be reconsidered based on protein  Construction of mutants with structural point mutations or deletion mutations
4Small-scale protein expression and purification1-2 weeksIn case of inclusion body expression, the time and method will be adjusted
5Large-scale protein expression and purificationAccording to the expression volumeIt can be selected from shake flask or fermentor culture

Remarks:

You can choose any of the above experimental content, or a combination of related experimental content according to the experimental needs;

During purification, affinity purification, ion column purification, hydrophobic packing purification and molecular sieve purification are used; the characteristics of the protein itself and the choice of expression system will affect the purity and activity of the final protein;

Related Articles:

protein expression in e coli

Medicilon’s Yeast Two Hybrid Services

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...